Hypoadiponectinemia, dyslipidemia, and impaired growth in children with HIV-associated facial lipoatrophy

Roy J. Kim, Dean C. Carlow, Jessica H. Rutstein, Richard M. Rutstein

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: To compare growth, lipids and adipocytokines in HIV-positive children with and without lipoatrophy. Patients: Eleven HIV-positive children with facial lipoatrophy, and 22 age- and sex-matched HIV-positive controls without signs of fat abnormality. Methods: Clinical data including height, physical examination findings, medications, markers of viral control, cholesterol, and triglycerides were retrieved from the medical charts. Serum samples were analyzed for adiponectin, inflammatory markers, and high density lipoprotein cholesterol (HDL). Results: Lipoatrophy was associated with higher triglycerides (330 vs 133 mg/dl, p = 0.0003), lower HDL (33 vs 48 mg/dl, p = 0.02), and a greater frequency of hypercholesterolemia (total cholesterol >200 mg /dl; 64% vs 23%, p <0.03). Adiponectin was 53% lower in patients with lipodystrophy (6.9 μg/ml vs 14.8 μg/ml, p = 0.005), however there was no difference in the inflammatory markers soluble TNFα receptor 2 or interleukin 6. Strikingly, despite similar BMI z-scores and virological control, lipoatrophic patients were shorter by 1 standard deviation score (p = 0.03). Conclusions: The presence of facial lipoatrophy in a child with HIV infection is a marker for significant metabolic derangements including dyslipidemia and hypoadiponectinemia, and suggests the need for careful growth evaluation.

Original languageEnglish (US)
Pages (from-to)65-74
Number of pages10
JournalJournal of Pediatric Endocrinology and Metabolism
Volume20
Issue number1
StatePublished - Jan 2007

Fingerprint

Dyslipidemias
Adiponectin
HIV
HDL Cholesterol
Triglycerides
Growth
Cholesterol
Lipodystrophy
Adipokines
Tumor Necrosis Factor Receptors
Hypercholesterolemia
Physical Examination
HIV Infections
Interleukin-6
Biomarkers
Fats
Lipids
Serum
Hypoadiponectinemia

Keywords

  • Adiponectin
  • Child
  • Growth
  • HIV
  • Lipids
  • Lipoatrophy
  • Lipodystrophy

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

Hypoadiponectinemia, dyslipidemia, and impaired growth in children with HIV-associated facial lipoatrophy. / Kim, Roy J.; Carlow, Dean C.; Rutstein, Jessica H.; Rutstein, Richard M.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 20, No. 1, 01.2007, p. 65-74.

Research output: Contribution to journalArticle

Kim, Roy J. ; Carlow, Dean C. ; Rutstein, Jessica H. ; Rutstein, Richard M. / Hypoadiponectinemia, dyslipidemia, and impaired growth in children with HIV-associated facial lipoatrophy. In: Journal of Pediatric Endocrinology and Metabolism. 2007 ; Vol. 20, No. 1. pp. 65-74.
@article{b48e14adaf4049e696550917b7c78955,
title = "Hypoadiponectinemia, dyslipidemia, and impaired growth in children with HIV-associated facial lipoatrophy",
abstract = "Objective: To compare growth, lipids and adipocytokines in HIV-positive children with and without lipoatrophy. Patients: Eleven HIV-positive children with facial lipoatrophy, and 22 age- and sex-matched HIV-positive controls without signs of fat abnormality. Methods: Clinical data including height, physical examination findings, medications, markers of viral control, cholesterol, and triglycerides were retrieved from the medical charts. Serum samples were analyzed for adiponectin, inflammatory markers, and high density lipoprotein cholesterol (HDL). Results: Lipoatrophy was associated with higher triglycerides (330 vs 133 mg/dl, p = 0.0003), lower HDL (33 vs 48 mg/dl, p = 0.02), and a greater frequency of hypercholesterolemia (total cholesterol >200 mg /dl; 64{\%} vs 23{\%}, p <0.03). Adiponectin was 53{\%} lower in patients with lipodystrophy (6.9 μg/ml vs 14.8 μg/ml, p = 0.005), however there was no difference in the inflammatory markers soluble TNFα receptor 2 or interleukin 6. Strikingly, despite similar BMI z-scores and virological control, lipoatrophic patients were shorter by 1 standard deviation score (p = 0.03). Conclusions: The presence of facial lipoatrophy in a child with HIV infection is a marker for significant metabolic derangements including dyslipidemia and hypoadiponectinemia, and suggests the need for careful growth evaluation.",
keywords = "Adiponectin, Child, Growth, HIV, Lipids, Lipoatrophy, Lipodystrophy",
author = "Kim, {Roy J.} and Carlow, {Dean C.} and Rutstein, {Jessica H.} and Rutstein, {Richard M.}",
year = "2007",
month = "1",
language = "English (US)",
volume = "20",
pages = "65--74",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "1",

}

TY - JOUR

T1 - Hypoadiponectinemia, dyslipidemia, and impaired growth in children with HIV-associated facial lipoatrophy

AU - Kim, Roy J.

AU - Carlow, Dean C.

AU - Rutstein, Jessica H.

AU - Rutstein, Richard M.

PY - 2007/1

Y1 - 2007/1

N2 - Objective: To compare growth, lipids and adipocytokines in HIV-positive children with and without lipoatrophy. Patients: Eleven HIV-positive children with facial lipoatrophy, and 22 age- and sex-matched HIV-positive controls without signs of fat abnormality. Methods: Clinical data including height, physical examination findings, medications, markers of viral control, cholesterol, and triglycerides were retrieved from the medical charts. Serum samples were analyzed for adiponectin, inflammatory markers, and high density lipoprotein cholesterol (HDL). Results: Lipoatrophy was associated with higher triglycerides (330 vs 133 mg/dl, p = 0.0003), lower HDL (33 vs 48 mg/dl, p = 0.02), and a greater frequency of hypercholesterolemia (total cholesterol >200 mg /dl; 64% vs 23%, p <0.03). Adiponectin was 53% lower in patients with lipodystrophy (6.9 μg/ml vs 14.8 μg/ml, p = 0.005), however there was no difference in the inflammatory markers soluble TNFα receptor 2 or interleukin 6. Strikingly, despite similar BMI z-scores and virological control, lipoatrophic patients were shorter by 1 standard deviation score (p = 0.03). Conclusions: The presence of facial lipoatrophy in a child with HIV infection is a marker for significant metabolic derangements including dyslipidemia and hypoadiponectinemia, and suggests the need for careful growth evaluation.

AB - Objective: To compare growth, lipids and adipocytokines in HIV-positive children with and without lipoatrophy. Patients: Eleven HIV-positive children with facial lipoatrophy, and 22 age- and sex-matched HIV-positive controls without signs of fat abnormality. Methods: Clinical data including height, physical examination findings, medications, markers of viral control, cholesterol, and triglycerides were retrieved from the medical charts. Serum samples were analyzed for adiponectin, inflammatory markers, and high density lipoprotein cholesterol (HDL). Results: Lipoatrophy was associated with higher triglycerides (330 vs 133 mg/dl, p = 0.0003), lower HDL (33 vs 48 mg/dl, p = 0.02), and a greater frequency of hypercholesterolemia (total cholesterol >200 mg /dl; 64% vs 23%, p <0.03). Adiponectin was 53% lower in patients with lipodystrophy (6.9 μg/ml vs 14.8 μg/ml, p = 0.005), however there was no difference in the inflammatory markers soluble TNFα receptor 2 or interleukin 6. Strikingly, despite similar BMI z-scores and virological control, lipoatrophic patients were shorter by 1 standard deviation score (p = 0.03). Conclusions: The presence of facial lipoatrophy in a child with HIV infection is a marker for significant metabolic derangements including dyslipidemia and hypoadiponectinemia, and suggests the need for careful growth evaluation.

KW - Adiponectin

KW - Child

KW - Growth

KW - HIV

KW - Lipids

KW - Lipoatrophy

KW - Lipodystrophy

UR - http://www.scopus.com/inward/record.url?scp=34047265158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047265158&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 65

EP - 74

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 1

ER -